Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.63 |
| ▸ | CTSK | P43235 | 7/20 | 0.43 |
| ▸ | CTSL | P07711 | 6/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.43 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 7/20 | 0.42 |
| ▸ | MMP9 | P14780 | 5/20 | 0.42 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP3 | P08254 | 3/20 | 0.42 |
| ▸ | MMP7 | P09237 | 3/20 | 0.42 |
| ▸ | MMP8 | P22894 | 3/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.42 |
| ▸ | MMP20 | O60882 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | MMP10 | P09238 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | MMP15 | P51511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8297607 | 1.00 | MMP12 (0.63) | MMP12CTSKCTSLCTSSANPEP | |
| SCHEMBL1610444 | 0.92 | MMP12 (0.55) | MMP12CTSKCTSLCTSSANPEP | |
| SCHEMBL8297606 | 0.90 | MMP12 (0.53) | MMP12CTSKCTSLCTSSANPEP | |
| SCHEMBL8298929 | 0.86 | MMP12 (0.74) | MMP12CTSKCTSLCTSSANPEP | |
| SCHEMBL8300835 | 0.86 | MMP12 (0.74) | MMP12CTSKCTSLCTSSANPEP | |
| SCHEMBL12714138 | 0.86 | MMP12 (0.63) | MMP12ANPEPLTA4HMMP2MMP9 | |
| SCHEMBL12714116 | 0.83 | MMP12 (0.45) | MMP12CTSKCTSLCTSSMMP2 | |
| SCHEMBL8300920 | 0.83 | MMP12 (0.65) | MMP12CTSKCTSLCTSSANPEP | |
| SCHEMBL12714131 | 0.83 | MMP12 (0.64) | MMP12ANPEPLTA4HMMP2MMP9 | |
| SCHEMBL12714200 | 0.81 | MMP12 (0.43) | MMP12CTSKCTSLCTSSMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309579-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-11-13 | — | — | US | disclosed |
| US-20110281891-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-11-17 | — | — | US | disclosed |
| US-7998964-B2 | hydroxy((2S)-2-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}-4-methylpentyl)formamide ; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative disorders, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO S.A. (CH) | 2011-08-16 | — | — | US | disclosed |
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2011-04-14 | — | — | US | disclosed |
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2011-04-14 | — | — | US | disclosed |
| US-7879876-B2 | matrix metalloproteinase inhibitors such as N-{1-[(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)methyl]-3-phenylpropyl}-N-hydroxy formamide; prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular disorders, neurodegenerative diseases, cancer, respiratory system disorders and fibrosis | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | disclosed |
| US-7838522-B2 | Benzothiazole formulations and use thereof | ARES TRADING S.A. (CH) | 2010-11-23 | — | — | US | disclosed |
| US-20100035943-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035943-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | LABORATOIRES SERONO SA (CH) | 2009-09-03 | — | — | US | disclosed |
| US-20080275060-A1 | N-Hydroxyamide Derivatives and Use Thereof | LABORATOIRES SERONO SA (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2008-09-18 | — | — | US | disclosed |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2008-09-18 | — | — | US | disclosed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | disclosed |
| US-7358265-B2 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (R&D) LTD | 2008-04-15 | — | — | US | disclosed |
| US-7358265-B2 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (R&D) LTD | 2008-04-15 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| EP-1476438-B1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2004101537-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | MGLL, MBOAT4, MBOAT1 | MMP12 2620/4885CTSK 944/4885CTSL 445/4885 |
| US-20100035943-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | MMP12, TIMP3, MMP9 | MMP12 1/4885CTSK 821/4885CTSL 544/4885 |
| US-20110281891-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | MMP12 690/4885CTSK 1886/4885CTSL 1433/4885 |
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | MMP12, STS, MMP14 | MMP12 1/4885CTSK 295/4885CTSL 355/4885 |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | MMP12 1/4885CTSK 821/4885CTSL 544/4885 |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | PPP1R1B, PPP5C, PPP3CA | MMP12 1846/4885CTSK 3774/4885CTSL 3941/4885 |
| US-20080275060-A1 | N-Hydroxyamide Derivatives and Use Thereof | HNMT, HCAR2, HPGD | MMP12 690/4885CTSK 1886/4885CTSL 1433/4885 |
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | MMP12 1/4885CTSK 821/4885CTSL 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.